.webp)
Researchers at the University of Maryland uncover mechanisms in RNA interference that could lead to more effective treatments for high cholesterol, liver diseases, and cancers.
A new study from the University of Maryland offers new insights into RNA interference (RNAi) and its potential to enhance drug efficacy for treating various human diseases. Published on August 20, 2024, in eLife, this research examines RNAi mechanisms using microscopic roundworms as a model, aiming to address the longevity and effectiveness of RNAi-based therapies.
RNAi therapeutics, which target and silence disease-causing genes: have shown promise in treating genetic disorders, viral infections, and cancers. However, questions remain about their durability and optimization. Antony Jose, an associate professor of cell biology and molecular genetics at UMD, and his team explored these issues by analyzing RNAi in non-dividing cells within roundworms.
Their findings revealed that RNAi effects diminish over time, even in cells that do not divide. This surprising discovery points to a degradation mechanism affecting RNAi's efficacy. The team identified three critical regulatory proteins that influence gene silencing, providing new avenues to enhance and sustain RNAi-based treatments.
Jose emphasizes the need to address potential drug resistance and optimize dosing schedules for RNAi therapies. "Understanding how these proteins interact and how RNAi effects are degraded can help in designing more effective and durable treatments," he said.
The study's insights could lead to advancements in RNAi-based drugs for conditions like high cholesterol and cancer, paving the way for tailored and long-lasting therapeutics. The research was supported by the NIH and NSF.
.webp)
